Recently, the Class 1.1 innovative traditional Chinese medicine (TCM) Compound Binafuxi Granules of Xinjiang Yinduolan Uighur Medicine Co., Ltd. is approved for marketing by China NMPA.

This product is a compound preparation formulated based on Uyghur medicine theory. It has undergone a randomized, double-blind, placebo-controlled, multicenter clinical trial and has demonstrated efficacy in clearing abnormal bodily fluids. It is indicated for the treatment of febrile common cold, with symptoms such as fever, nasal congestion, runny nose, sore throat, headache, dry mouth, etc. This drug provides a new treatment option for patients with febrile common colds, as diagnosed by TCM and Uyghur medicine differentiation in the case of common colds.